Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
RAD.US
id: 413
E.D. Pennsylvania
Court
On September 29, 2022, Rite Aid (RAD) disclosed a $252.2 million charge for the impairment of goodwill related to the Company’s Elixir subsidiary. Later on an earnings call, Rite the Company's CFO, Matt Schroeder, explained that the large impairment charge was triggered by a change in Rite Aid’s estimate of lives covered by Elixir for 2023 based on the latest selling season.

On this news, Rite Aid’s stock price dropped 28%, seriously damaging investors.

Earlier in the year, the Company made the following statements and reports:
  • In Rite Aid’s Q1 2023 earnings call on June 23, 2022, CEO, Donigan stated concerning the PBM services business that “our strong network contracts, new rebate capabilities, innovative clinical services and expertise in government programs have enabled us to add 80,000 new lives for January 1, 2023 start date. These are more new lives than we sold last year. And additionally, the selling season is still in progress, and we've got close to 1 million lives remaining in the pipeline for January 1, 2023.” On the same call, Elixir’s COO, Chris DuPaul, advised that “we’ve had a pretty strong start to our selling season, particularly on the health plan side. ”
  • In a letter to shareholders, dated June 10, 2022, appearing in Rite Aid’s 2022 Notice of Annual Meeting of Stockholders and Proxy Statement, Defendant Donigan stated, “our Elixir account and sales teams are gaining momentum, and we are executing more efficiently by consolidating functions. And the market is noticing—we have added 34,000 individuals covered by Elixir’s PBM services since January 1, 2022, with many more in the pipeline.”
  • In Rite Aid’s Q4 2022 earnings call on April 14, 2022, Rite Aid’s President and CEO, Heyward Rutledge Donigan, addressed the growth of Elixir’s PBM services business during the selling season ending January 1, 2023, stating that (i) in the past few months, Elixir had already “sold 35,000 new members” (as against a total of 55,000 new members in the prior year), (ii) Elixir was a finalist for 150,000 additional new members, and “results have shown that once we get to finalist, we’re winning deals 35% of the time,” and (iii) Elixir had “a current pipeline of nearly 1 million members and growing.”
Taking all the facts and statements of the Company's management into account, the shareholders have every reason to suspect that Rite and its Leaders breached fundamental fiduciary duties to them.

Alleged Offence
Financial Misrepresentation
Fraud
Failure to Disclose
Malpractice
Negligence
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
29 September 2022
Collecting participants…

Rite Aid Corporation

Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Ret...

    Ticker
    RAD.US
    ISIN
    US7677548726
    CIK
    84129
    Sector
    Healthcare
    Industry
    Pharmaceutical Retailers
    Country
    USA
    Address
    1200 Intrepid Avenue, Philadelphia, PA, United States